Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer

14 Sept 2023

Abstract excerpt

Background: Opioids are the primary analgesics for cancer pain. Recent clinical evidence suggests opioids may counteract the effect of immune checkpoint inhibition (ICI) immunotherapy, but the mechanism for this interaction is unknown. The following experiments study how opioids and immunotherapy modulate a common RNA expression pathway in triple negative breast cancer (TNBC), a cancer subtype in which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Pain Management and Opioid Use

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37781176
DOI: 10.3389/fonc.2023.1267532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancerPMID 37781176Read ↗

Advances in immunotherapy for triple-negative breast cancerSemantic proximity Read ↗

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast CancerSemantic proximity Read ↗

The IL-8/NF-κB feedback loop confers a paclitaxel-sensitive/doxorubicin-resistant phenotype in triple-negative breast cancerSemantic proximity Read ↗

Cancer Pain is Not One Size Fits All: Evolving from Tradition to PrecisionSemantic proximity Read ↗

Eribulin represses effector T cell differentiation and enhances T cell-mediated anti-tumor activity to triple negative breast cancer cells through the facilitation of CD8+ T cell proliferationSemantic proximity Read ↗

Cancer pain: current practice and emerging targetsSemantic proximity Read ↗

Neoadjuvant immune-modulating SBRT and anti-CD73 to increase response to anti-PD-L1 and chemotherapy in early ER+/HER2- breast cancer: primary endpoint and translational results from the randomized Neo-CheckRay trialSemantic proximity Read ↗

Loss of Neuroligin 4X Induces An Intrinsic Innate Immune Response in TNBCSemantic proximity Read ↗

Combinatorial Immunotherapies Overcome MYC-Driven Immune EvasionSemantic proximity Read ↗

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells.Semantic proximity Read ↗

Reduced glutamate decarboxylase 1 underlies morphine-promoted lung metastasis of triple-negative breast cancer in miceSemantic proximity Read ↗

Evolving Paradigms in Cancer Pain Management: From Opioid-Centric Care to Multimodal and Personalized StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.